Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q08462

UPID:
ADCY2_HUMAN

ALTERNATIVE NAMES:
ATP pyrophosphate-lyase 2; Adenylate cyclase type II; Adenylyl cyclase 2

ALTERNATIVE UPACC:
Q08462; B7Z2C1; Q2NKL8; Q9UDB2; Q9UPU2

BACKGROUND:
The enzyme Adenylate cyclase type 2, with alternative names ATP pyrophosphate-lyase 2 and Adenylyl cyclase 2, is crucial for cAMP signaling molecule formation following G-protein signaling. It facilitates changes in gene expression, leading to increased IL6 production, and is active in signaling cascades related to muscarinic acetylcholine receptors.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Adenylate cyclase type 2 offers a promising avenue for developing new therapeutic approaches. Its key role in signaling pathways that regulate gene expression and immune responses positions it as a valuable target for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.